Page 82 - Drug Class Review

placebo at 26 weeks (WMD -2.1; 95% CI: -2.6 – -1.5), and for RIV 1- 4 mg/d (WMD -0.8; 95% CI:
severe dementia against those showing moderate or mild dementia revealed significant benefit at 26
Meta-analysis of ADAS-Cog WMDs reveals statistically significant benefit of RIV 6/12 mg/d over
Page 71 of 205
Drug Effectiveness Review Project
weeks for RIV 6-12 mg/d (55%, 579/1056 showed the worse condition compared to 59%, 511/868;
1.6);
those showing > 4 points improvement at 26 weeks shows benefit of cognitive function for RIV 6-
12 mg/d (83%, 878/1054 did not show 4 points improvement compared to 89%, 787/863; OR 0.6;
impression, functional performance, cognitive function, behavioral disturbance, QOL, effect on caregiver,
95% CI: 0.4 – 0.8), but NOT for the 1-4 mg/d (88%, 571/650 did not show 4 points improvement
ITT meta-analysis of ADAS-Cog dichotomized into those showing < 4 points improvement and
RIV given at any dose with parallel placebo control; outcome measures included: dependency, global

death, institutionalization rates, withdrawals, incidence of adverse events

-1.5 – -0.2); pooled results across doses not presented

presented. compared to 90%, 576/643; OR 0.84; 95% CI: 0.60 – 1.19); pooled results across does not ITT meta-analysis for MMSE shows similar results to ADAS-Cog at 26 weeks; 6-12 mg/d WMD -0.83; 95% CI: -1.12 – -0.53 and 1-4 mg/d WMD -0.43; 95% CI: -0.78 – -0.08 ITT analysis of CIBIC-plus dichotomized into those showing no change or decline against those showing improvement shows there are benefits to 1-4 mg/d at 26 weeks (74%, 457/614 showed no improvement compared with 80%, 500/623; OR 0.71; 95% CI: 0.55 – 0.93), and for 6-12 mg/d (73%, 715/

• • • • • •

Final Report Update 1 Authors: Birks et al. Year: 2004 CHARACTERISTICS OF INTERVENTIONS: MAIN RESULTS: Alzheimer's Drugs